Skip to main content
. 2014 Jan 1;20(1):31–41. doi: 10.1089/ars.2012.5119

FIG. 5.

FIG. 5.

Effect of NaHS on cAMP rebound, AC mRNA levels in SH-SY5Y cells treated with DAMGO. (A) NaHS pretreatment attenuated cAMP rebound induced by opioid withdrawal in SH-SY5Y cells. Cells were treated with DAMGO (10 μM) for 24 h followed by addition of naloxone (100 μM) (D+Nal) or washing the cell with low-serum medium (D+W) to induce opioid withdrawal. NaHS (10 μM) was given 10 min before the addition of DAMGO. Mean±S.E.M., n=6–12. **p<0.01, ***p<0.001, versus the corresponding values without NaHS treatment in the same group; ##p<0.01, ###p<0.001, versus D (DAMGO alone without NaHS treatment). (B) Naloxone-induced cAMP rebound was abolished by NaHS (10 μM) given 10 min before the addition of DAMGO (S+D+Nal), but not by NaHS given 30 min before the addition of naloxone (D+S+Nal). Mean±S.E.M, n=6. ***p<0.001, versus Con; ###p<0.001, versus D;+++p<0.001, versus D+Nal. (C, D) NaHS pretreatment abolished DAMGO-induced up-regulation of mRNA level of AC1 and AC8 in SH-SY5Y cells. Mean±S.E.M, n=4–6. **p<0.01, versus Con; ##p<0.01, versus D. Con, control; FSK, forskolin; S, NaHS; D, DAMGO; Nal, naloxone; Veh, vehicle; DAMGO, [D-Ala2,N-Me-Phe4,Gly5-ol]-Enkephalin.